Inozyme Pharma Inc.
(INZY)
undefined
undefined%
At close: undefined
2.99
-0.83%
After-hours Dec 13, 2024, 04:10 PM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to
free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY01 |
| Net Income | -71.17M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M | - |
| Depreciation & Amortization | 833.00K | 744.00K | 674.00K | 217.00K | 83.00K | 26.00K | - |
| Stock-Based Compensation | 7.04M | 7.67M | 7.16M | 2.31M | 301.00K | 444.00K | - |
| Other Working Capital | -1.70M | 1.86M | 760.00K | -2.21M | 684.00K | 629.00K | - |
| Other Non-Cash Items | -4.29M | -1.13M | 378.00K | 18.04M | -71.00K | -4.37M | - |
| Deferred Income Tax | - | - | 170.00K | - | - | - | - |
| Change in Working Capital | -3.08M | 2.01M | 85.00K | -111.00K | 601.00K | 1.43M | - |
| Operating Cash Flow | -70.67M | -57.76M | -48.15M | -35.97M | -18.81M | -9.44M | - |
| Capital Expenditures | -298.00K | -410.00K | -397.00K | -568.00K | -139.00K | -259.00K | - |
| Acquisitions | - | 4.99K | -43.19K | 116.61K | 8.25K | - | - |
| Purchase of Investments | -269.33M | -151.99M | -121.97M | -177.92M | -24.66M | -13.57M | - |
| Sales Maturities Of Investments | 215.98M | 147.00M | 165.16M | 61.31M | 16.41M | 22.83M | - |
| Other Investing Acitivies | - | -4.99K | 43.19K | -116.61K | -8.25K | 9.27M | - |
| Investing Cash Flow | -53.65M | -5.40M | 42.80M | -117.18M | -8.39M | 9.01M | - |
| Debt Repayment | 40.00M | 4.05M | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - | - |
| Dividend Paid | - | - | - | - | - | - | - |
| Other Financial Acitivies | 322.00K | 12.60M | 609.00K | 33.84M | 22.97M | 31.95M | - |
| Financial Cash Flow | 125.97M | 72.79M | 609.00K | 149.81M | 22.97M | 31.95M | - |
| Net Cash Flow | 1.63M | 9.60M | -4.72M | -3.34M | -4.23M | 31.51M | - |
| Free Cash Flow | -70.97M | -58.17M | -48.55M | -36.54M | -18.95M | -9.70M | - |